Charles & Colvard, Ltd. - CTHR Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles & Colvard, Ltd. in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CTHR shares.
View CTHR analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1-year price targets for Charles & Colvard, Ltd.'s shares. Their CTHR share price forecasts range from $3.75 to $3.75. On average, they expect the company's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 182.0% from the stock's current price.
View analysts price targets for CTHR or view top-rated stocks among Wall Street analysts.

Charles & Colvard, Ltd.'s stock was trading at $2.89 on January 1st, 2022. Since then, CTHR stock has decreased by 54.0% and is now trading at $1.33.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, September 1st 2022.
View our CTHR earnings forecast.

Charles & Colvard, Ltd. (NASDAQ:CTHR) announced its quarterly earnings results on Thursday, November, 4th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.01. The business had revenue of $10.28 million for the quarter, compared to the consensus estimate of $9.20 million. Charles & Colvard, Ltd. had a trailing twelve-month return on equity of 18.57% and a net margin of 24.63%. During the same period in the previous year, the business posted $0.03 earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles & Colvard, Ltd. investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Golar LNG Partners (GMLP), Novan (NOVN), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS).

Charles & Colvard, Ltd. trades on the NASDAQ under the ticker symbol "CTHR."

Charles & Colvard, Ltd.'s stock is owned by a number of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (0.97%) and Founders Capital Management (0.07%). Insiders that own company stock include Clint J Pete, Don O'connell, Neal I Goldman, Ollin B Sykes and Suzanne Miglucci.
View institutional ownership trends.

Shares of CTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTHR stock can currently be purchased for approximately $1.33.

Charles & Colvard, Ltd. (NASDAQ:CTHR) has a market capitalization of $40.82 million and generates $39.24 million in revenue each year. The company earns $12.81 million in net income (profit) each year or $0.35 on an earnings per share basis.

Charles & Colvard, Ltd.'s mailing address is 170 SOUTHPORT DRIVE, MORRISVILLE NC, 27560. The official website for the company is www.charlesandcolvard.com. The company can be reached via phone at (919) 468-0399, via email at ir@charlesandcolvard.com, or via fax at 919-468-0486.